428 filings
Page 5 of 22
DEFA14A
bwown290 mwrhqgt3t
25 Jun 21
Additional proxy soliciting materials
4:48pm
8-K
qpf8ugj1esdtmv31mowl
25 Jun 21
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
4:46pm
8-K
zo8867
9 Jun 21
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
9:06am
8-K
yc8s ke956
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
0s9etj0d
29 Apr 21
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
10:07am
UPLOAD
ein 0a78ylw7e0mr8fe
7 Apr 21
Letter from SEC
12:00am
8-K
5qnvvcat
23 Mar 21
Other Events
8:21am
8-K
pcede7
11 Mar 21
Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021
8:38am
8-K
6wrcvm4pxn bsu7o
17 Feb 21
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8:06am
424B5
76bz699vqt9j712822fk
16 Feb 21
Prospectus supplement for primary offering
5:11pm
424B5
50p go23u0xepq6
16 Feb 21
Prospectus supplement for primary offering
6:03am
FWP
vzh7nj
12 Feb 21
Free writing prospectus
5:29pm
8-K
styq7ljrm6y8mvuy3
10 Feb 21
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
9:03am
8-K
0fw6n fwk2wlpt2
28 Jan 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES JANUARY 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
4:30pm